Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Healthcare-associated infections (HAIs) pose a significant threat to patient safety and clinical outcomes, often exacerbated by increasing antibiotic resistance. Current methods of infection control may not be sufficient to prevent the spread of bacteria in clinical and home settings. There is a need for innovative materials that can actively prevent bacterial colonization and infection.
Solution
Amferia develops and manufactures medical materials incorporating antimicrobial peptides designed to proactively eliminate bacteria. These materials mimic the body's natural immune system to kill bacteria without harming the body, even drug-resistant strains. The core technology is a platform applicable to various products, including wound dressings, pre-surgical antibacterial patches, antimicrobial sprays, and antibacterial coatings for medical devices. Amferia's technology aims to reduce the reliance on traditional antibiotics, offering a sustainable approach to combatting antibiotic resistance.
Target Audience
The primary target audience includes hospitals, clinics, veterinary practices, and medical device manufacturers seeking advanced antimicrobial solutions to improve patient outcomes and reduce the risk of infection.
Features
- Antimicrobial peptides that kill 99.99% of bacteria on contact.
- Non-toxic and biocompatible materials suitable for direct contact with skin and tissue.
- Broad-spectrum efficacy against a wide range of bacteria, including antibiotic-resistant strains.
- Customizable formulations for integration into various medical devices and applications.
- Hydrogel wound dressings for both human and veterinary use.
- Patented technology with granted patents in Europe, the U.S., and China.